Successful use of phosphodiesterase type 5 inhibitors to control symptomatic esophageal hypercontractility: a case report.
Agrawal
Amit
A
Digestive Diseases Center, Medical University of South Carolina, 96 Jonathan Lucas Street, 210 Clinical Sciences Building, Charleston, South Carolina 29425, USA, agrawala@musc.edu
Tutuian
Radu
R
Hila
Amine
A
Castell
Donald O
DO
D000328:Adult; D002243:Carbolines / Q000627:therapeutic use*; D015154:Esophageal Motility Disorders / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use; D000068581:Tadalafil; D014227:Triazines / Q000627:therapeutic use; D000069058:Vardenafil Dihydrochloride
D002243:Carbolines; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride; D000068581:Tadalafil; D000068677:Sildenafil Citrate